NASDAQ:ASRT Assertio (ASRT) Stock Forecast, Price & News $6.02 -0.19 (-3.06%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$6.01▼$6.3050-Day Range$5.00▼$7.6652-Week Range$2.07▼$8.01Volume1.20 million shsAverage Volume2.00 million shsMarket Capitalization$335.31 millionP/E Ratio3.99Dividend YieldN/APrice Target$9.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Assertio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.8% Upside$9.50 Price TargetShort InterestBearish17.79% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$910,646 Sold Last QuarterProj. Earnings Growth83.33%From $0.36 to $0.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector192nd out of 986 stocksPharmaceutical Preparations Industry84th out of 475 stocks 3.5 Analyst's Opinion Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Assertio has a forecasted upside of 57.8% from its current price of $6.02.Amount of Analyst CoverageAssertio has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.79% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Assertio has recently increased by 3.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASRT. Previous Next 2.6 News and Social Media Coverage News SentimentAssertio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Assertio this week, compared to 3 articles on an average week.Search InterestOnly 24 people have searched for ASRT on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows13 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 117% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $910,646.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Assertio is held by insiders.Percentage Held by InstitutionsOnly 33.31% of the stock of Assertio is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Assertio are expected to grow by 83.33% in the coming year, from $0.36 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is 3.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is 3.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.01.Price to Earnings Growth RatioAssertio has a PEG Ratio of 1.71. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAssertio has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Assertio (NASDAQ:ASRT) StockAssertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.Read More Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesJune 6, 2023 | msn.comAssertio Holdings Stock Is Setting Up AgainMay 26, 2023 | finance.yahoo.comDoes Assertio Holdings (NASDAQ:ASRT) Deserve A Spot On Your Watchlist?June 8, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 25, 2023 | americanbankingnews.comAssertio Holdings, Inc. (NASDAQ:ASRT) Director Sells $651,787.80 in StockMay 14, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Assertio Holdings, Inc. Boosted by Analyst (NASDAQ:ASRT)May 13, 2023 | americanbankingnews.comLake Street Capital Raises Assertio (NASDAQ:ASRT) Price Target to $9.00May 12, 2023 | msn.comLake Street Maintains Assertio Holdings (ASRT) Buy RecommendationMay 12, 2023 | americanbankingnews.comAssertio (NASDAQ:ASRT) Downgraded by StockNews.com to HoldJune 8, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 11, 2023 | msn.comBWS Financial Maintains Assertio Holdings (ASRT) Buy RecommendationMay 11, 2023 | americanbankingnews.comAssertio (NASDAQ:ASRT) Price Target Increased to $10.00 by Analysts at BWS FinancialMay 10, 2023 | msn.comRecap: Assertio Holdings Q1 EarningsMay 10, 2023 | washingtonpost.comAssertio: Q1 Earnings SnapshotMay 10, 2023 | finance.yahoo.comAssertio Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 9, 2023 | finance.yahoo.comAssertio Holdings, Inc.'s (NASDAQ:ASRT) largest shareholders are individual investors with 58% ownership, institutions own 40%May 9, 2023 | finance.yahoo.comAssertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 OutlookMay 8, 2023 | americanbankingnews.comAssertio Holdings, Inc. (NASDAQ:ASRT) Director Sells $258,858.00 in StockMay 5, 2023 | finance.yahoo.comAssertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern TimeApril 27, 2023 | finance.yahoo.comAssertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023April 25, 2023 | finance.yahoo.comAssertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR TransactionApril 17, 2023 | finance.yahoo.comThe Market Doesn't Like What It Sees From Assertio Holdings, Inc.'s (NASDAQ:ASRT) Earnings YetMarch 31, 2023 | americanbankingnews.comShort Interest in Assertio Holdings, Inc. (NASDAQ:ASRT) Rises By 57.8%March 23, 2023 | fool.comAssertio (NASDAQ: ASRT)March 10, 2023 | finance.yahoo.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | finance.yahoo.comAssertio Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 6, 2023 | finance.yahoo.comAssertio Appoints Dr. Howard Franklin as Senior Vice President, MedicalMarch 3, 2023 | finance.yahoo.comAssertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should KnowSee More Headlines ASRT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASRT Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+53.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.51 Trailing P/E Ratio4.10 Forward P/E Ratio17.19 P/E Growth1.71Net Income$109.63 million Net Margins59.86% Pretax Margin9.74% Return on Equity52.50% Return on Assets26.35% Debt Debt-to-Equity Ratio0.15 Current Ratio1.46 Quick Ratio1.29 Sales & Book Value Annual Sales$156.23 million Price / Sales2.21 Cash Flow$3.00 per share Price / Cash Flow2.06 Book Value$4.67 per share Price / Book1.33Miscellaneous Outstanding Shares55,700,000Free Float51,300,000Market Cap$344.78 million OptionableOptionable Beta1.39 Key ExecutivesMr. Daniel A. Peisert (Age 48)Pres, CEO & Director Comp: $2.18MMr. Paul Schwichtenberg (Age 52)Sr. VP & CFO Comp: $780.88kMr. Ajay Patel (Age 39)Sr. VP & Chief Accounting Officer Comp: $742.01kMr. Bill IskosSr. VP of OperationsMr. Sam SchlessingerSr. VP & Gen. CounselMr. Jeff ChristensenSr. VP of CommercialDr. Howard J. Franklin M.B.A.M.D., Sr. VP of MedicalMore ExecutivesKey CompetitorsALX OncologyNASDAQ:ALXOSavaraNASDAQ:SVRAPrecigenNASDAQ:PGENCOMPASS PathwaysNASDAQ:CMPSAstria TherapeuticsNASDAQ:ATXSView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 109,150 shares on 5/22/2023Ownership: 0.470%Heather L MasonSold 89,286 sharesTotal: $651,787.80 ($7.30/share)Geode Capital Management LLCBought 33,371 shares on 5/16/2023Ownership: 0.823%Susquehanna Fundamental Investments LLCSold 8,171 shares on 5/16/2023Ownership: 0.413%Balyasny Asset Management L.P.Bought 38,365 shares on 5/16/2023Ownership: 0.069%View All Insider TransactionsView All Institutional Transactions ASRT Stock - Frequently Asked Questions Should I buy or sell Assertio stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASRT shares. View ASRT analyst ratings or view top-rated stocks. What is Assertio's stock price forecast for 2023? 3 brokers have issued 12 month target prices for Assertio's stock. Their ASRT share price forecasts range from $9.00 to $10.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 53.5% from the stock's current price. View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts. How have ASRT shares performed in 2023? Assertio's stock was trading at $4.30 at the start of the year. Since then, ASRT shares have increased by 44.0% and is now trading at $6.19. View the best growth stocks for 2023 here. When is Assertio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our ASRT earnings forecast. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.20. The business earned $42.47 million during the quarter, compared to analysts' expectations of $37.78 million. Assertio had a trailing twelve-month return on equity of 52.50% and a net margin of 59.86%. What ETFs hold Assertio's stock? ETFs with the largest weight of Assertio (NASDAQ:ASRT) stock in their portfolio include Hartford Multifactor Small Cap ETF (ROSC).Barrons 400 ETF (BFOR). What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK). What is Assertio's stock symbol? Assertio trades on the NASDAQ under the ticker symbol "ASRT." Who are Assertio's major shareholders? Assertio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.62%), Acadian Asset Management LLC (2.07%), BlackRock Inc. (1.73%), American Century Companies Inc. (1.16%), Two Sigma Investments LP (1.16%) and Arrowstreet Capital Limited Partnership (1.07%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Group LP Cr, Heather L Mason, James L Tyree and Paul Schwichtenberg. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Assertio's stock price today? One share of ASRT stock can currently be purchased for approximately $6.19. How much money does Assertio make? Assertio (NASDAQ:ASRT) has a market capitalization of $344.78 million and generates $156.23 million in revenue each year. The company earns $109.63 million in net income (profit) each year or $1.51 on an earnings per share basis. How can I contact Assertio? Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The official website for the company is www.assertiotx.com. The company can be reached via phone at (224) 419-7106, via email at investor@assertiotx.com, or via fax at 510-744-8001. This page (NASDAQ:ASRT) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.